The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_004360.5(CDH1):c.1565+1G>C

CA16614968

406622 (ClinVar)

Gene: CDH1
Condition: CDH1-related diffuse gastric and lobular breast cancer
Inheritance Mode: Autosomal dominant inheritance
UUID: 08051975-97cf-4ea2-ba42-18d87d4a1a4b

HGVS expressions

NM_004360.5:c.1565+1G>C
NM_004360.5(CDH1):c.1565+1G>C
NC_000016.10:g.68815760G>C
CM000678.2:g.68815760G>C
NC_000016.9:g.68849663G>C
CM000678.1:g.68849663G>C
NC_000016.8:g.67407164G>C
NG_008021.1:g.83469G>C
ENST00000261769.10:c.1565+1G>C
ENST00000261769.9:c.1565+1G>C
ENST00000422392.6:c.1382+1G>C
ENST00000562836.5:n.1636+1G>C
ENST00000566510.5:c.*231+1G>C
ENST00000566612.5:c.1565+1G>C
ENST00000611625.4:c.1628+1G>C
ENST00000612417.4:c.1565+1G>C
ENST00000621016.4:c.1565+1G>C
NM_004360.3:c.1565+1G>C
NM_001317184.1:c.1382+1G>C
NM_001317185.1:c.17+1G>C
NM_001317186.1:c.-255+1G>C
NM_004360.4:c.1565+1G>C
NM_001317184.2:c.1382+1G>C
NM_001317185.2:c.17+1G>C
NM_001317186.2:c.-255+1G>C

Pathogenic

Met criteria codes 5
PVS1_Strong PP1_Strong PM2_Supporting PS4 PM5_Supporting
Not Met criteria codes 21
PM6 PM1 PM3 PM4 BA1 BS2 BS3 BS4 BS1 BP2 BP3 BP4 BP1 BP5 BP7 PS1 PS3 PS2 PP4 PP3 PP2

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen CDH1 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 3.1

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
CDH1 VCEP
The c.1565+1G>C variant is a canonical splice variant predicted to result in a truncated or absent protein (PVS1_Strong, PM5_Supporting). The variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant has been reported in at least four families meeting HDGC clinical criteria (PS4; PMID: 26182300, SCV000545383.5 and internal laboratory contributor). This variant was also found to co-segregate with disease in multiple affected family members, with at least nine meioses observed across four families (PP1_Strong; SCV000545383.5, SCV000665081.3 and internal laboratory contributor). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Strong, PS4, PP1_Strong, PM2_Supporting, PM5_Supporting.
Met criteria codes
PVS1_Strong
Canonical +1 splice site in intron 10. Predicted by SpliceAI to abolish the native donor site and activate a cryptic donor 6 bp into the intron (creates PTC) or exon skipping. Both expected to lead to NMD
PP1_Strong
9 affected segregations over 4 families (Ambry, Invitae, NCI)
PM2_Supporting
Absent in gnomAD v2.1.1 and v3.0 in a region of sufficient coverage
PS4
At least 4 families that meet HDGC clinical criteria (NCI, Invitae, PMID: 26182300). 5 families with missing pathology or age of diagnosis information to meet clinical criteria.
PM5_Supporting
Apply PM5_Supporting to the variant with the alteration at canonical splicing site.
Not Met criteria codes
PM6
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BA1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP7
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
Approved on: 2023-08-28
Published on: 2023-08-28
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.